Form 4: Repligen Corp Executive Ralf Kuriyel Reports Acquisition of Restricted Stock Units and Stock Options

Senior VP of R&D at Repligen Corp, Ralf Kuriyel, reports the acquisition of 3,520 restricted stock units and 3,497 stock options.

Summary

• Ralf Kuriyel, Senior VP of R&D at Repligen Corporation, filed a Form 4 on February 29, 2024.
• The report details the acquisition of 3,520 restricted stock units on February 27, 2024, at a price of $0.00.
• These restricted stock units vest in equal annual installments over three years, starting February 27, 2025.
• Kuriyel also acquired 3,497 stock options with an exercise price of $192.71 on the same date.
• These options vest annually, starting February 27, 2025, and expire on February 27, 2034.
• Following these transactions, Kuriyel directly owns 27,076 shares of Repligen Corp common stock and 3,497 stock options.

Sentiment

Score: 7

Explanation: The document reflects a standard executive compensation practice, which is generally viewed neutrally to positively as it aligns management interests with shareholders. The sentiment is moderately positive due to the incentive structure.

Positives

• The acquisition of restricted stock units and stock options aligns the executive's interests with those of the shareholders.
• The vesting schedule encourages long-term commitment from the executive.

Future Outlook

The document does not contain any specific forward-looking statements regarding the company's future performance.

Industry Context

Stock options and restricted stock units are common forms of executive compensation in the biotechnology industry, aligning management's interests with those of shareholders and incentivizing long-term value creation. This is a standard practice among companies like Repligen and its peers.

Comparison to Industry Standards

• Executive compensation packages including stock options and restricted stock units are standard practice in the biotech industry.
• Companies like Danaher, Thermo Fisher Scientific, and Sartorius also utilize similar compensation structures to incentivize their executives.
• The vesting schedules and exercise prices are generally aligned with industry norms to promote long-term growth and shareholder value.

Stakeholder Impact

• Shareholders: The granting of stock options and restricted stock units can align management's interests with those of shareholders, potentially leading to increased shareholder value.
• Employees: The compensation structure can motivate employees through leadership.

Key Dates